Results 171 to 180 of about 229,829 (311)

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Dysregulation of renin-angiotensin-aldosterone axis in septic shock: Emerging roles of angiotensin-(1-5) and alamandine. [PDF]

World J Crit Care Med
Srinivasan A, Dhivya P.
europepmc   +1 more source

Serum IGF‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) increases cardiovascular and kidney disease risk. Insulin‐like growth factor 1 (IGF‐1) regulates metabolic and vascular function, but its role in long‐term cardio‐kidney outcomes (CKO) in MASLD remains unclear.
Yongin Cho, Hye‐Sun Park, Tae Seop Lim, Jong Ho Jhee, Jong Hyun Jhee   +4 more
wiley   +1 more source

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). Materials and Methods Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to
David Z. I. Cherney, Peter Rossing, Maria Eugenia Canziani, Maria Luiza Caramori, Ricardo Correa‐Rotter, Lisa Cronin, Christian Hugo, Bo Ji, Juliane Meyerhoff, Masaomi Nangaku, Arnold Silva, Dorothea Urbach, Shimoli V. Shah, Dick de Zeeuw, Katherine R. Tuttle   +14 more
wiley   +1 more source

Long-term patiromer adherence and renin-angiotensin aldosterone system inhibitor utilization: A retrospective study. [PDF]

World J Nephrol
Kleinman N, Desai T, Thakar C.
europepmc   +1 more source

Does the Combination of Abdominal Obesity and Vitamin D Deficiency Increase the Risk of Death in Individuals Aged 50 or Older? Evidence From the ELSA Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Despite the known association between abdominal obesity (AO) and vitamin D deficiency, it remains unclear whether this combination is associated with higher mortality risk. We investigated whether the coexistence of AO and vitamin D deficiency elevates the risk of death.
Joyce da Silva Milliati, Thaís Barros Pereira da Silva, Roberta de Oliveira Máximo, Mariane Marques Luiz, Sara Souza Lima, Andrew Steptoe, Cesar de Oliveira, Tiago da Silva Alexandre   +7 more
wiley   +1 more source

COVID and the Renin-Angiotensin System: Are Hypertension or Its Treatments Deleterious?

Frontiers in Cardiovascular Medicine, 2020
Florian Zores, Mathieu E. Rebeaud
doaj   +1 more source

Dysregulated Aldosterone Production in Obesity Is Associated With Adverse Cardiac Structure, Function, and Adiposity. [PDF]

Circulation
Tsai CH, Chan JM, Milks J, Ferrebus A, Hanna I, Mahrokhian S, Newman AJ, Parisien-La Salle S, Reis Marques I, Foote K, Adler GK, Kwong RY, Jerosch-Herold M, Pitt B, Vaidya A, Brown JM.   +15 more
europepmc   +1 more source

Kinetic and structural characterisation of domain‐specific angiotensin I‐converting enzyme inhibition by captopril, rentiapril and zofenoprilat

The FEBS Journal, EarlyView.
Angiotensin I‐converting enzyme (ACE) contains two catalytic domains (nACE and cACE) and is a key therapeutic target for hypertension and cardiovascular disease. Current ACE inhibitors (ACEi) nonselectively inhibit both domains, causing adverse effects. Selective inhibition requires an understanding of domain‐specific binding.
Kyle S. Gregory, Vinasha Ramasamy, Edward D. Sturrock, K. Ravi Acharya   +3 more
wiley   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source